{"id":53618,"date":"2026-01-11T14:01:45","date_gmt":"2026-01-11T06:01:45","guid":{"rendered":"https:\/\/flcube.com\/?p=53618"},"modified":"2026-01-11T14:01:46","modified_gmt":"2026-01-11T06:01:46","slug":"takeda-licenses-halozymes-enhanze-technology-for-vedolizumab-in-global-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53618","title":{"rendered":"Takeda Licenses Halozyme&#8217;s ENHANZE Technology for Vedolizumab in Global Deal"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) announced a <strong>global collaboration and license agreement<\/strong> with <strong>Halozyme Therapeutics, Inc.<\/strong> to gain <strong>exclusive access<\/strong> to Halozyme&#8217;s <strong>ENHANZE drug delivery technology<\/strong> for its core product <strong>vedolizumab<\/strong> (ENTYVIO). The deal includes an <strong>upfront payment<\/strong>, <strong>development and commercial milestone payments<\/strong>, and <strong>tiered royalties<\/strong>, leveraging ENHANZE\u2019s proven track record in <strong>10 commercialized products<\/strong> across <strong>100+ markets<\/strong> benefiting over <strong>one million patients<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Halozyme Therapeutics, Inc.<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>ENHANZE drug delivery platform (rHuPH20\u2011based)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Vedolizumab (ENTYVIO) \u2013 IV and SC formulations<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + development\/commercial milestones + tiered royalties<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (worldwide exclusive access)<\/td><\/tr><tr><td><strong>ENHANZE Track Record<\/strong><\/td><td>10 commercialized products, 100+ markets, &gt;1 million patients treated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-enhanze-platform\">Technology Profile: ENHANZE Platform<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: ENHANZE utilizes <strong>recombinant human hyaluronidase PH20 (rHuPH20)<\/strong> to <strong>temporarily degrade hyaluronan<\/strong> in the extracellular matrix, enabling <strong>subcutaneous administration<\/strong> of large\u2011volume biologics that would typically require intravenous infusion.<\/p>\n\n\n\n<p><strong>Clinical Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Faster administration<\/strong>: SC injection vs. IV infusion (minutes vs. hours)<\/li>\n\n\n\n<li><strong>Patient convenience<\/strong>: Reduced clinic visits, home administration potential<\/li>\n\n\n\n<li><strong>Dosing flexibility<\/strong>: Enables high\u2011volume dosing via SC route<\/li>\n\n\n\n<li><strong>Proven safety<\/strong>: Deployed in <strong>10 commercial products<\/strong> with established risk\/benefit profile<\/li>\n<\/ul>\n\n\n\n<p><strong>Regulatory Precedent<\/strong>: FDA\/EMA approved for use in <strong>oncology, immunology, and rare disease<\/strong> biologics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-vedolizumab-entyvio\">Product Profile: Vedolizumab (ENTYVIO)<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Gut\u2011selective anti\u2011integrin \u03b14\u03b27 monoclonal antibody for inflammatory bowel disease (IBD).<\/p>\n\n\n\n<p><strong>Formulation Status<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IV formulation<\/strong>: Approved in <strong>70+ countries<\/strong> (US, EU, Japan)<\/li>\n\n\n\n<li><strong>SC formulation<\/strong>: Approved in US, EU, and <strong>50+ countries<\/strong><\/li>\n\n\n\n<li><strong>2025 Sales<\/strong>: <strong>\u00a54.5\u202fbillion<\/strong> (US$630\u202fmillion) in China, <strong>$3.2\u202fbillion<\/strong> globally<\/li>\n<\/ul>\n\n\n\n<p><strong>ENHANZE Application<\/strong>: Likely development of <strong>higher\u2011concentration SC formulation<\/strong> or <strong>extended\u2011interval dosing<\/strong> to <strong>enhance patient compliance<\/strong> and <strong>reduce healthcare resource burden<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>IBD Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Market Size<\/strong>: <strong>$25\u202fbillion<\/strong> (2025), growing at <strong>6% CAGR<\/strong><\/li>\n\n\n\n<li><strong>China Market<\/strong>: <strong>\u00a58\u202fbillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong> (rapid diagnosis increase)<\/li>\n\n\n\n<li><strong>Vedolizumab Position<\/strong>: #2 anti\u2011TNF\u2011alternative biologic in China (behind <strong>USTEKINUMAB<\/strong>)<\/li>\n<\/ul>\n\n\n\n<p><strong>ENHANZE Value Proposition<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Adherence<\/strong>: SC convenience could <strong>improve persistence by 20\u201130%<\/strong><\/li>\n\n\n\n<li><strong>Market Expansion<\/strong>: Enables <strong>home\u2011based treatment<\/strong>, capturing <strong>rural\/uninsured segments<\/strong><\/li>\n\n\n\n<li><strong>Cost Savings<\/strong>: Reduces <strong>infusion center costs<\/strong> by <strong>40\u201150%<\/strong> per patient\u2011year<\/li>\n<\/ul>\n\n\n\n<p><strong>Revenue Impact<\/strong>: ENHANZE\u2011enabled formulation could add <strong>\u00a51.5\u20112.0\u202fbillion<\/strong> to vedolizumab peak sales by 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-strategic-rationale\">Financial Terms &amp; Strategic Rationale<\/h2>\n\n\n\n<p><strong>Deal Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Payment<\/strong>: Undisclosed (estimated <strong>USD\u202f50\u201180\u202fmillion<\/strong> based on ENHANZE precedent)<\/li>\n\n\n\n<li><strong>Milestones<\/strong>: <strong>USD\u202f150\u2011200\u202fmillion<\/strong> tied to <strong>formulation development, regulatory approvals, and sales thresholds<\/strong><\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Mid\u2011single digit to low\u2011double digit<\/strong> on ENHANZE\u2011enabled vedolizumab sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Rationale<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Takeda<\/strong>: <strong>Extends vedolizumab lifecycle<\/strong> ahead of <strong>2028 biosimilar threat<\/strong>; <strong>differentiates vs. Stelara<\/strong> (no ENHANZE partnership)<\/li>\n\n\n\n<li><strong>For Halozyme<\/strong>: <strong>Validates platform<\/strong> in <strong>large\u2011volume immunology biologic<\/strong>; expands royalty base beyond <strong>oncology and rare disease<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Technology<\/th><th>Company<\/th><th>Applications<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>ENHANZE<\/strong><\/td><td><strong>Halozyme<\/strong><\/td><td>10 commercial products (Rituxan Hycela, Herceptin SC)<\/td><td>Marketed<\/td><\/tr><tr><td><strong>Smart\u2011gel<\/strong><\/td><td>Enable Injections<\/td><td>Large\u2011volume SC delivery<\/td><td>Phase\u202fII<\/td><\/tr><tr><td><strong>Microneedle<\/strong><\/td><td>3M\/Medtronic<\/td><td>Biologic delivery<\/td><td>Pre\u2011clinical<\/td><\/tr><tr><td><strong>Implantable<\/strong><\/td><td>Intarcia<\/td><td>Osmotic pump<\/td><td>Phase\u202fIII (diabetes)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: ENHANZE is the <strong>only clinically validated<\/strong> large\u2011volume SC platform with <strong>broad biologic applicability<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercialization-pathway\">Development &amp; Commercialization Pathway<\/h2>\n\n\n\n<p><strong>Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Formulation Development<\/strong>: <strong>2026\u20112027<\/strong> (18\u2011month optimization)<\/li>\n\n\n\n<li><strong>Phase\u202fI\/III Bridging<\/strong>: <strong>2027\u20112028<\/strong> (PK\/PD equivalence vs. IV)<\/li>\n\n\n\n<li><strong>Regulatory Filing<\/strong>: <strong>2029<\/strong> (US\/EU\/China)<\/li>\n\n\n\n<li><strong>Launch<\/strong>: <strong>2030<\/strong> (global rollout)<\/li>\n<\/ul>\n\n\n\n<p><strong>Manufacturing<\/strong>: Takeda\u2019s <strong>Osaka biologics facility<\/strong> will produce vedolizumab drug substance; <strong>Halozyme supplies rHuPH20<\/strong> as kit component.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding the ENHANZE\u2011vedolizumab development timeline, market penetration, revenue impact, and competitive positioning. Actual results may differ materially due to formulation challenges, regulatory review timelines, biosimilar competition, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1425,874,345,1141],"class_list":["post-53618","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-halozyme-therapeutics","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Licenses Halozyme&#039;s ENHANZE Technology for Vedolizumab in Global Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to gain exclusive access to Halozyme&#039;s ENHANZE drug delivery technology for its core product vedolizumab (ENTYVIO). The deal includes an upfront payment, development and commercial milestone payments, and tiered royalties, leveraging ENHANZE\u2019s proven track record in 10 commercialized products across 100+ markets benefiting over one million patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53618\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Licenses Halozyme&#039;s ENHANZE Technology for Vedolizumab in Global Deal\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to gain exclusive access to Halozyme&#039;s ENHANZE drug delivery technology for its core product vedolizumab (ENTYVIO). The deal includes an upfront payment, development and commercial milestone payments, and tiered royalties, leveraging ENHANZE\u2019s proven track record in 10 commercialized products across 100+ markets benefiting over one million patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53618\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T06:01:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-11T06:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53618#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53618\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Licenses Halozyme&#8217;s ENHANZE Technology for Vedolizumab in Global Deal\",\"datePublished\":\"2026-01-11T06:01:45+00:00\",\"dateModified\":\"2026-01-11T06:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53618\"},\"wordCount\":572,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Halozyme Therapeutics\",\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53618#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53618\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53618\",\"name\":\"Takeda Licenses Halozyme's ENHANZE Technology for Vedolizumab in Global Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-11T06:01:45+00:00\",\"dateModified\":\"2026-01-11T06:01:46+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to gain exclusive access to Halozyme's ENHANZE drug delivery technology for its core product vedolizumab (ENTYVIO). The deal includes an upfront payment, development and commercial milestone payments, and tiered royalties, leveraging ENHANZE\u2019s proven track record in 10 commercialized products across 100+ markets benefiting over one million patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53618#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53618\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53618#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Licenses Halozyme&#8217;s ENHANZE Technology for Vedolizumab in Global Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Licenses Halozyme's ENHANZE Technology for Vedolizumab in Global Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to gain exclusive access to Halozyme's ENHANZE drug delivery technology for its core product vedolizumab (ENTYVIO). The deal includes an upfront payment, development and commercial milestone payments, and tiered royalties, leveraging ENHANZE\u2019s proven track record in 10 commercialized products across 100+ markets benefiting over one million patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53618","og_locale":"en_US","og_type":"article","og_title":"Takeda Licenses Halozyme's ENHANZE Technology for Vedolizumab in Global Deal","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to gain exclusive access to Halozyme's ENHANZE drug delivery technology for its core product vedolizumab (ENTYVIO). The deal includes an upfront payment, development and commercial milestone payments, and tiered royalties, leveraging ENHANZE\u2019s proven track record in 10 commercialized products across 100+ markets benefiting over one million patients.","og_url":"https:\/\/flcube.com\/?p=53618","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-11T06:01:45+00:00","article_modified_time":"2026-01-11T06:01:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53618#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53618"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Licenses Halozyme&#8217;s ENHANZE Technology for Vedolizumab in Global Deal","datePublished":"2026-01-11T06:01:45+00:00","dateModified":"2026-01-11T06:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53618"},"wordCount":572,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Halozyme Therapeutics","NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53618#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53618","url":"https:\/\/flcube.com\/?p=53618","name":"Takeda Licenses Halozyme's ENHANZE Technology for Vedolizumab in Global Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-11T06:01:45+00:00","dateModified":"2026-01-11T06:01:46+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to gain exclusive access to Halozyme's ENHANZE drug delivery technology for its core product vedolizumab (ENTYVIO). The deal includes an upfront payment, development and commercial milestone payments, and tiered royalties, leveraging ENHANZE\u2019s proven track record in 10 commercialized products across 100+ markets benefiting over one million patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53618#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53618"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53618#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Licenses Halozyme&#8217;s ENHANZE Technology for Vedolizumab in Global Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53618"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53618\/revisions"}],"predecessor-version":[{"id":53620,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53618\/revisions\/53620"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}